FierceBiotechOriginal article
{"a":[{"_":"BioVie’s stock sinks 50% as company uses composite endpoint to make case for Parkinson’s program","$":{"href":"/biotech/biovie-uses-composite-endpoint-make-case-parkinsons-program","hreflang":"en"}}]}
Phase 2MixedbezisterimNegative
AI Analysis
Summary
BioVie announced phase 2 data for bezisterim in Parkinson's disease, but the company emphasized a composite endpoint and subpopulation analysis rather than its stated primary endpoint, causing the stock to sink 50%.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
Company reported phase 2 data as evidence of meaningful advance, but relied on composite endpoint rather than stated primary endpoint and emphasized subpopulation outcomes
Importance:6/10
Sentiment:
-0.70
phase_2_dataprimary_endpoint_misscomposite_endpointparkinson's_diseasestock_decline
Related Companies
Read the original article
Published by FierceBiotech on August 6, 2026 9:40 AM